Antiplatelet and anticoagulation therapy during percutaneous coronary interventions: A review for the interventionalist. (19th June 2018)

• Record Type: Journal Article
• Authors: Basman, Craig; Tariq, Afnan; Parmar, Yuvrajsinh J.; Asti, Deepak; Coplan, Neil L.; Singh, Varinder P.; Reimers, Carl D.
• Is Part Of: Journal of interventional cardiology. Volume 31:Number 5(2018:Oct.)
• Page Start: 693
• Page End: 704
• Publication Date: 2018-06-19
• Subjects: antiplatelet -- anticoagulation -- percutaneous coronary intervention; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; 616.1206
• DOI: 10.1111/joic.12529
• Languages: English
• ISSNs: 0896-4327

Abstract

Abstract : Pharmacotherapy for percutaneous coronary interventions is essential to optimize the balance between thrombosis and bleeding. Currently, choices abound for the selection of antiplatelet and anticoagulation therapies during percutaneous intervention (PCI). This review article discusses the mechanisms, pharmacokinetics/dynamics, and clinical data behind the various pharmacotherapies including; aspirin, thienopyridines, glycoprotein IIb/IIIa inhibitors, vorapaxar, heparin, direct thrombin inhibitors, and factor Xa inhibitors.